Denosumab Improves Bone Disease in Kidney Transplant Recipients
The medication inhibits bone resorption but is associated with prolonged elevation in PTH levels that require treatment.
The medication inhibits bone resorption but is associated with prolonged elevation in PTH levels that require treatment.
The cumulative incidence of bone fractures was below 5% in BPA recipients.
Etelcalcetide use in patients with diabetic nephropathy might protect against development of adynamic bone disease, according to investigators.
Bone loss in patients with kidney stone disease, particularly in men, has been underappreciated in clinical practice, according to investigators.
Odds of BMD testing up with history of osteoporosis, rheumatoid arthritis, bisphosphonate use.
Fracture prevention efforts should be considered in patients with CKD of any age, according to investigators.
Rapid decline in atypical fracture risk seen when bisphosphonate discontinued in women ≥50 years.
For those with previous vertebral fracture, major osteoporotic fractures increased with holidays >12 months.
Increase in risk with long delay of subsequent doses not significant for composite of all fracture types.
This study is the first placebo-controlled clinical trial to investigate a treatment for MRONJ in patients for whom the condition is established.